L3VLUP
ProSign in

AXSM · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

AXSMLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • AXSM
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterAXSMLLY
Q3 20201 holders, $2.1m33 holders, $14.1bn
Q4 2020none listed holders, n.a.29 holders, $17.3bn
Q1 20211 holders, $2.5m24 holders, $23.0bn
Q2 2021none listed holders, n.a.24 holders, $27.8bn
Q3 20212 holders, $12m31 holders, $29.9bn
Q4 2021none listed holders, n.a.31 holders, $34.7bn
Q1 20222 holders, $12m24 holders, $35.3bn
Q2 20221 holders, $2.6m33 holders, $42.7bn
Q3 20222 holders, $37m31 holders, $43.4bn
Q4 20224 holders, $75m31 holders, $46.6bn
Q1 20234 holders, $146m33 holders, $44.3bn
Q2 20236 holders, $92m37 holders, $59.6bn
Q3 20234 holders, $78m44 holders, $67.6bn
Q4 20234 holders, $120m45 holders, $73.6bn
Q1 20243 holders, $59m41 holders, $95.3bn
Q2 20244 holders, $65m43 holders, $110bn
Q3 20246 holders, $86m45 holders, $107bn
Q4 20243 holders, $38m46 holders, $93.9bn
Q1 20259 holders, $222m42 holders, $98.4bn
Q2 20257 holders, $139m43 holders, $93.2bn
Q3 20255 holders, $284m39 holders, $86.7bn
Q4 202512 holders, $806m41 holders, $123bn
Q1 202612 holders, $708m39 holders, $106bn
Q2 202617 holders, $1.4bn44 holders, $132bn
AXSM

Axsome Therapeutics Inc

Holders
4
Reported value
$65m
Buyers
2
Sellers
1

Breadth +1 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
43
Reported value
$110bn
Buyers
29
Sellers
17

Breadth +12 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2024

Among the 45 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only AXSM (2)

Farallon Capital Management LLC, Point72 Asset Management LP

Only LLY (41)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Arrowstreet Capital LP, Artisan Partners LP, Balyasny Asset Management LLC, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Caxton Associates LLP, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, ExodusPoint Capital Management LP, Fidelity (FMR LLC), GAMCO Investors Inc, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, and 16 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →